-
2023-507936-20-00
5
2025-05-05
Acute myeloid leukemia
-
2024-517062-42-00
5
2025-05-02
melanoma, cutaneous malignant
-
2024-515245-42-00
3
2025-04-24
Ewing Sarcoma
-
2024-514459-14-00
4
2025-04-22
Non-Small Cell Lung Cancer
-
2024-513054-30-00
5
2025-04-16
Moderately to Severely Active Crohn's Disease (CD)
-
2022-501854-12-01
1
2025-02-05
G12D/G12V Pancreatic Ductal Adenocarcinoma
-
2024-513077-48-00
5
2024-12-19
O6-methylguanine methyltransferase (MGMT) unmethylated glioblastoma
-
2024-511879-16-00
5
2024-12-12
Prurigo Nodularis
-
2024-512926-27-00
5
2024-12-12
patients with estrogen receptor-positive/human epidermal growth factor
-
2022-501095-25-01
5
2024-11-04
Pediatric Subjects with Infantile-onset Pompe Disease Aged 0 to < 18 Y
-
2023-507555-29-00
9
2024-08-16
LA/mGC/GEJC (locally advanced unresectable or metastatic gastric cance
-
2023-503699-25-00
5
2024-07-15
Progressive Pulmonary Fibrosis
-
2023-504214-30-00
5
2024-06-27
Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
-
2023-503697-21-01
5
2024-06-24
Idiopathic pulmonary fibrosis
-
2023-503904-10-00
5
2024-06-07
Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity
-
2023-504308-27-00
5
2024-06-06
non-squamous non-small cell lung cancer
-
2022-502405-15-01
4
2024-04-08
Mantle Cell Lymphoma (MCL)
-
2023-507402-13-00
5
2024-04-03
Multiple myeloma
-
2023-507039-39-00
5
2024-03-22
Moderate to Severe Plaque Psoriasis
-
2022-501606-35-01
11
2024-02-21
Platinum-sensitive epithelial ovarian, fallopian tube, or primary
peri
-
2023-503920-14-00
5
2024-01-02
Non-Small Cell Lung Cancer (NSCLC)
-
2022-503058-37-00
5
2023-11-10
Advanced Gastrointestinal Stromal Tumor
-
2023-504247-13-00
4
2023-10-17
Large cell neuroendocrine carcinoma
-
2022-502959-54-00
5
2023-09-26
Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Ep